We forecast WuXi's revenue growth to be slower ... WuXi plans to fund its capacity expansion primarily with its own capital. We assign a narrow moat rating to WuXi Biologics due to switching ...

Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

Going forward, we forecast WuXi's revenue growth to ... WuXi plans to fund its capacity expansion primarily with its own capital. We assign a narrow moat rating to WuXi Biologics due to its ...

A year after the Biosecure Act was introduced, WuXi AppTec’s US revenue growth continued to drop significantly, and the ...

Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...

Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million ...

WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...

WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

Talents People are WuXi Biologics' greatest assets ... Sustainability The Group has integrated Sustainability as a core pillar of its business growth strategy, earning widespread recognition from ...

HONG KONG, March 25, 2025 /PRNewswire/ -- WuXi Biologics ... to the biologics industry, fast growing technology platforms including ADCs and bispecific antibodies; (iii) growth of research ...

The growth was primarily driven by ... which adheres to the highest global quality standards. Talents People are WuXi Biologics' greatest assets. As of December 31, 2024, the Group's total ...